Stage IIIA Hepatocellular Carcinoma, Stage IIIB Hepatocellular Carcinoma, Stage IIIC Hepatocellular Carcinoma, Stage IVA Hepatocellular Carcinoma, Stage IVB Hepatocellular Carcinoma
Conditions
Brief summary
The purpose of this study is to identify maximum tolerated dose (MTD), that is, the highest dose of the study drug nivolumab that does not cause unacceptable side effects, for combination treatment of nivolumab and yttrium Y 90 glass microspheres (Y-90). Also, to evaluate the efficacy (the effect of drug on your tumor) and the tolerability (the effect of the drug on your body) of nivolumab, when given with standard of care Y-90 (Therasphere). Nivolumab is currently Food and Drug Administration (FDA) approved for other cancers, but has not yet been investigated in advanced or refractory hepatocellular carcinoma. Nivolumab is an antibody (a human protein that sticks to a part of the tumor and/or immune cells) designed to allow the body's immune system to work against tumor cells. Y-90 is currently FDA approved for the treatment of hepatocellular carcinomas, but has not yet been investigated in combination with nivolumab for this disease.
Detailed description
PRIMARY OBJECTIVES: I. To identify MTD of nivolumab for combination treatment of nivolumab and Y-90 in this population. SECONDARY OBJECTIVES: I. To evaluate the proportion of patients with objective response rate (ORR) (according to Response Evaluation Criteria in Solid Tumors \[RECIST\] criteria) to the combination treatment of nivolumab with Y-90. II. To evaluate the proportion of patients alive and progression free at 24 weeks in the described population. III. To evaluate the toxicities (according to the National Comprehensive Cancer Network \[NCCN\] Common Terminology Criteria for Adverse Events \[CTCAE\] version (v)4.03) and tolerability of nivolumab and Y-90 in patients with advanced hepatocellular carcinoma IV. To determine the disease control rate (DCR) to the combination of nivolumab and Y-90 at 24 months from the start of nivolumab treatment. TERTIARY OBJECTIVES: I. Programmed cell death 1 ligand 1 (PD-L1) protein on tumor cells and the expression levels of other markers of inflammatory/immune signature that may include but not be limited to programmed cell death protein 1 (PD-1), tumor necrosis factor receptor superfamily, member 4 (OX40), cluster of differentiation (CD) 73, CD39, T cell immunoglobulin and T-cell immunoglobulin and mucin-domain containing-3 (TIM3), glucocorticoid-induced tumour necrosis factor receptor (GITRL), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), CD3, CD4, CD8, CD45RO, forkhead box P3 (FOXP3), and granzyme by immunohistochemistry (IHC) and/or flow cytometry will be evaluated. II. Whole exome sequencing and computational analyses will be performed to assess mutanome and immunome (subpopulations of immune cells). III. Change in clonal burden landscape of various mutanome and immunome will be analyzed to investigate its correlation with treatment response or development of resistance to treatment. OUTLINE: This is a phase I, dose-escalation study of nivolumab followed by a phase Ib study. Patients receive yttrium Y 90 glass microspheres intraarterially (IA). Approximately 7-14 days after Y-90 administration. A delay of 4 weeks will be permitted in case of toxicity. After yttrium Y 90 glass microspheres treatment, nivolumab will be administered intravenously (IV) over approximately 60 minutes every 2 weeks until disease progression, unacceptable toxicity, or withdrawal of consent. After completion of study treatment, patients are followed up 30 days after the last dose of nivolumab and again at 100 days after discontinuing study drug.
Interventions
OTHERLaboratory Biomarker Analysis
Correlative studies
BIOLOGICALNivolumab
Given IV
RADIATIONYttrium Y 90 Glass Microspheres
Given IA
Sponsors
Bristol-Myers Squibb
National Cancer Institute (NCI)
Northwestern University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have a diagnosis of hepatocellular carcinoma (HCC) confirmed by American Association for Study of Liver Diseases (AASLD) guidelines with a Childs-Pugh score of A or B (but, =\< Childs score B8) * NOTE: If the patient does not have histological confirmation of disease by biopsy, diagnosis of HCC must be documented with approval by a tumor board or other multidisciplinary conference * Patients must have at least 1 lesion that is measurable using RECIST guidelines. NOTE: A previously irradiated lesion can be considered a target lesion if the lesion is well defined, measurable per RECIST, and has clearly progressed. NOTE: For patients with infiltrative disease, evaluable disease needs to be confirmed by pathology if RECIST measurements cannot be made. * Patients must have advanced disease that is not amenable to transplant or resection * Patients may be treatment naive or have received any number of prior therapies * NOTE: Prior immunotherapy is contraindicated and not permitted * Patients with chronic hepatitis B are eligible as long as they have evidence of ongoing viral replication (detectable hepatitis B surface antigen \[HBsAg\], hepatitis B envelope antigen \[HBeAg\], or hepatitis B virus \[HBV\] deoxyribonucleic acid \[DNA\]); they must have HBV DNA viral load \< 100 IU/mL at screening; in addition, they must be on antiviral therapy per regional standard of care guidelines prior to initiation of study therapy; if not on antiviral therapy at screening, then the subject must initiate treatment per regional standard of care guidelines at the time of consent; both HBeAg positive and negative patients will be included * Patients positive for hepatitis C are permitted if controlled with medication, in the opinion of the investigator * Patients must exhibit an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 * Patients must have adequate organ function within 14 days prior to registration as determined by: * Hematological (without growth factor support) * Hemoglobin \>= 8.5 g/dL (without the use of growth factors) * Absolute neutrophil count (ANC) \>= 1000 * Platelet count \>= 50 x 10\^9/L (without use of growth factors \[ie., interleukin 11 (oprelvekin)\]) * Prothrombin time (PT)/international normalized ratio (INR) =\< 2.3 or PT =\< 6 seconds above control * NOTE: Abnormal PT/INR may be considered, with documented principal investigator (PI) approval, if it is due to the use of anticoagulants; for such patients, a normal PT/INR must be available from before the start of anticoagulation treatment * Renal * Calculated creatinine clearance (CrCl) or 24-hour urine CrCl \> 50 mL/min (Cockcroft-Gault formula will be used to calculate CrCl) * Hepatic * Serum bilirubin =\< 3 times the upper limit of normal (ULN) * Aspartate aminotransaminase (AST) and alanine aminotransaminase (ALT) =\< 5 times ULN * Serum electrolytes * Lipase =\< 1.5 times ULN * Amylase =\< 1.5 times ULN * Potassium, sodium, magnesium, and calcium (corrected for serum albumin) =\< grade 1 or within the institutional ranges of normal; if clinically appropriate, electrolytes may be corrected and values reassessed prior to enrollment * Females of childbearing potential (FOCBP), and non-sterilized males who are sexually active must agree to the use of two methods of contraception, with one method being highly effective and the other method being either highly effective or less effective; they must also refrain from egg and/or sperm cell donation and breastfeeding for 90 days after the final dose of investigational product(s) * FOCBP are defined as those who are not surgically sterile (ie, bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or postmenopausal (defined as 12 months with no menses without an alternative medical cause) * Women of childbearing potential (WOCBP) must agree to follow instructions for method(s) of contraception for the duration of treatment with nivolumab plus 5 half-lives of nivolumab (19 weeks) plus 30 days (duration of ovulatory cycle) for a total of 23 weeks post-treatment completion. * Men who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with nivolumab plus 5 half-lives of the study drug (19 weeks) plus 90 days (duration of sperm turnover) for a total of 31 weeks post-treatment completion * FOCBP must have a negative pregnancy test within 7 days prior to registration * Note: FOCBP will have to have repeat pregnancy test within 24 hours of starting nivolumab, scheduled for cycle 1 day 1 * Subjects must provide archived tumor specimens for correlative biomarker studies if sufficient tissue is available; a fresh biopsy is not required * Patients must have the ability to understand and the willingness to sign a written informed consent prior to registration on study
Exclusion criteria
* Patients must not have had prior treatment with nivolumab or any other PDL1 or PD-1 antagonists * Patients must not have a history of severe allergic reactions (i.e., grade 4 allergy, anaphylactic reaction from which the subject did not recover within 6 hours of institution of supportive care) to any unknown allergens or any components of the nivolumab formulations * Patients diagnosed or treated for malignancy other than HCC are not eligible unless they meet one of the following exceptions: * Malignancy treated with curative intent and with no known active disease present for \>= 3 years before registration and felt to be at low risk for recurrence by the treating physician. * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease. * Adequately treated cervical carcinoma in situ without evidence of disease * Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including chronic prolonged systemic corticosteroids (defined as corticosteroid use of duration one month or greater), should be excluded; these include but are not limited to patients with a history of: * Immune related neurologic disease * Multiple sclerosis * Autoimmune (demyelinating) neuropathy * Guillain-Barre syndrome * Myasthenia gravis * Systemic autoimmune disease such as systemic lupus erythematosus (SLE) * Connective tissue diseases * Scleroderma * Inflammatory bowel disease (IBD) * Crohn's * Ulcerative colitis * Patients with a history of toxic epidermal necrolysis (TEN) * Stevens-Johnson syndrome * Anti-phospholipid syndrome * NOTE: Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll * Patients with renal failure currently requiring dialysis of any kind are not eligible * Patients with untreated central nervous system (CNS) metastatic disease (including spinal cord and leptomeningeal disease) are excluded * Note: Subjects with previously treated CNS metastases that are radiographically and neurologically stable for at least 6 weeks and do not require corticosteroids (of any dose) for symptomatic management are permitted to enroll * Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or the follow-up period of an interventional study, is excluded * Receipt of any investigational therapy is not permitted within 28 days prior to the first dose of nivolumab * Any concurrent chemotherapy, biologic or hormonal therapy for cancer treatment is not permitted within 28 days of registration * Note: Prior immunotherapy is not permitted * Note: Concurrent use of hormones for non-cancer-related conditions (e.g., insulin for diabetes and hormone replacement therapy) is acceptable * Patients with exposure to prior immunotherapy are not eligible * Patients are ineligible if they have unresolved toxicities from prior anticancer therapy, defined as having not resolved to National Cancer Institute (NCI) CTCAE version 4.03 grade 0 or 1 with the exception of alopecia and laboratory values listed per the inclusion criteria * Note: Subjects with irreversible toxicity that is not reasonably expected to be exacerbated by any of the investigational products may be included (eg, hearing loss) after consultation with the PI and Northwestern University (NU) Quality Assurance Monitor (QAM) * Radiation therapy is not permitted within 14 days of registration * Live vaccines are not permitted within 28 days of study registration * No systemic glucocorticoids will be permitted within 48 hours prior to study registration * Note: Topical steroids, bronchodilators and local steroid injections are permitted if clinically required * Patients with cardiac disease defined as one of the following are not eligible: * Congestive heart failure \> class II New York Heart Association (NYHA) * Unstable angina (anginal symptoms at rest) or new onset angina (began within the last 3 months) * Myocardial infarction within the past 6 months * Patients with cardiac ventricular arrhythmias requiring anti-arrhythmic therapy are not eligible * Patients with known human immunodeficiency virus (HIV) infection are not eligible * Patients must not have elevated lung shunting precluding treatment with Y-90 * Patients who have had major surgery within 4 weeks prior to registration are not eligible * Patients who have active clinically serious infection \> CTCAE grade 2 are not eligible * Patients with a history of gastrointestinal bleeding (GIB) within 6 weeks prior to registration are not eligible * Patients with prior transplant of any kind are not eligible * Known or suspected allergy to nivolumab or any agent given in the course of this trial is not permitted * Patients may not be pregnant or lactating at study registration * Patients who have an uncontrolled intercurrent illness including, but not limited to any of the following, are not eligible: * Hypertension (defined as \> 150/90) that is not controlled on medication * Ongoing or active infection requiring systemic treatment * Cardiac arrhythmia * Psychiatric illness/social situations that would limit compliance with study requirements * Any other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the patient's safety or study endpoints * Active alcohol use, drug use, or a psychiatric disease that would, in the opinion of the PI or a sub-investigator (sub-I), prevent the subject from complying with the study protocol and/or endanger the subject during their participation in the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum Tolerated Dose (MTD) | The first cycle of treatment with nivolumab (28 days) | To identify maximum tolerated dose (MTD) of nivolumab for combination treatment of nivolumab following Y-90 in patients with advanced hepatocellular carcinoma. The MTD will be defined as the highest dose of nivolumab that causes dose limiting toxicities (DLTs) in \<2 of 6 patients. The Phase I portion of the study follows a 3+3 dose escalation design. Nivolumab has two dose levels: Level 1: 80mg IV every 2 weeks, Level 2: 240mg IV every 2 weeks. Toxicity will be assessed using the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE), version 4.03. A DLT is defined as an Adverse Event (AE) or abnormal laboratory value assessed as at least possibly related to the study medication, occurs ≤ 28 days (1 cycle) following the first dose of nivolumab and meets any of the criteria listed in the Protocol (Section 4.3.1). |
| Phase IB: Objective Response Rate (ORR) | At baseline and every 8 weeks for the first 13 months and then every 12 weeks up to 2 years | Evaluate tumor response by assessing the proportion of patients with Objective response rate (ORR) (according to RECIST v. 1.1 criteria) to the combination treatment of nivolumab with Y-90 by examining imaging scans. Per RECIST v. 1.1: Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10mm. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival (PFS) at 24 Weeks (6 Months) | Up to 24 weeks (6 months) | Evaluate the percentage of patients alive and progression free at 24 weeks. PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. Progression assessment will be performed by investigator each time the patients has a radiologic evaluation after 8 weeks of treatment. In general Progressive Disease (PD) will be assessed using RECIST v1.1 and defined as: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm (0.5 cm). (Note: the appearance of one or more new lesions is also considered progression). |
| Number of Patients Who Experience Adverse Events | During treatment where (1 Cycle = 28 days) the range of cycles attempted was 1-14 and up to 100 days following the last administration of study drug | Safety and tolerability of toxicities (according to the NCCN CTCAE v4.03) and tolerability of nivolumab and y-90 in patients with advanced hepatocellular carcinoma as graded using CTCAE 4.03 that are grade 3 - 5 for patients determined to be evaluable for other endpoints. In general the following severity definitions are true: Mild (grade 1): the event causes discomfort without disruption of normal daily activities. Moderate (grade 2): the event causes discomfort that affects normal daily activities. Severe (grade 3): the event makes the patient unable to perform normal daily activities or significantly affects his/her clinical status. Life-threatening (grade 4): the patient was at risk of death at the time of the event. Fatal (grade 5): the event caused death. |
| Disease Control Rate (DCR) | At 24 weeks (6 months) | DCR will be determined at 24 weeks from the start of nivolumab treatment by the sum of complete response (CR), partial response (PR) and stable disease (SD) according to measurement of target and non-target lesions as assessed by RECIST v1.1 where generally the following definitions are true: CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10mm. PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum diameters while on study. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Circulating Free DNA (cfDNA) Mutation Analyses | Every 8 weeks for the first 24 weeks then every 16 weeks up to 2 years | Change in clonal burden landscape will be analyzed to investigate its correlation with treatment response or development of resistance to treatment. |
| PD-L1 Protein Expression | At baseline | Tumor tissue will be used to examine expression of PD-L1 protein on tumor cells. |
| Expression Level of Biomarker of Inflammatory/Immune Signature | Up to 2 years | Evaluate biomarker expression level using immunohistochemistry or flow cytometry. |
Countries
United States
Participant flow
Recruitment details
The study opened for accrual on July 25th, 2016 with goal of 40 patients. The first patient started treatment Sep. 12, 2016. The study design for Phase 1 was 3 + 3 dose escalation. Accrual was suspended on June 7, 2019 for review of DLT data for dose Level 2 of Phase 1. The study closed Jun. 2, 2020 due to funding issues and Phase 1b never opened.
Participants by arm
| Arm | Count |
|---|---|
| Phase I, Nivolumab Dose Lvl 1 (80mg IV Every 2 Weeks) Nivolumab was administered at 80mg as an intravenous infusion over 30 minutes (-5 minutes / +15 minutes) every 2 weeks (Day 1 & 15 of each cycle, 1 Cycle = 28 days). Courses repeated every cycle in the absence of disease progression or unacceptable toxicity.
Correlatives studies: Peripheral lymphocyte analysis, and analysis for PD-K1, PD-1, CD8+, and CD4+ tumor infiltrating lymphocytes. | 8 |
| Phase I, Nivolumab Dose Lvl 2 (240mg IV Every 2 Weeks) Nivolumab was administered at 240mg as an intravenous infusion over 30 minutes (-5 minutes / +15 minutes) every 2 weeks (Day 1 & 15 of each cycle, 1 Cycle = 28 days). Courses repeated every cycle in the absence of disease progression or unacceptable toxicity.
Correlatives studies: Peripheral lymphocyte analysis, and analysis for PD-K1, PD-1, CD8+, and CD4+ tumor infiltrating lymphocytes. | 9 |
| Phase 1b at Nivolumab MTD (240mg IV, Every 2 Weeks) The maximum tolerated dose of nivolumab was planned to be administered in patients recruited to Phase 1b, as an intravenous infusion over 30 minutes (-5 minutes / +15 minutes) every 2 weeks (Day 1 & 15 of each cycle, 1 Cycle = 28 days). Courses would repeat every cycle in the absence of disease progression or unacceptable toxicity.
Correlatives studies: Peripheral lymphocyte analysis, and analysis for PD-K1, PD-1, CD8+, and CD4+ tumor infiltrating lymphocytes.
Phase 1b never opened to accrual due to funding issues. | 0 |
| Total | 17 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| 2 Year Follow-up | Death | 6 | 7 | 0 |
| Cycle 1 (DLT Monitoring Period) | Adverse Event | 0 | 2 | 0 |
| Cycle 1 (DLT Monitoring Period) | Progressive Disease | 2 | 0 | 0 |
| Cycle 1 (DLT Monitoring Period) | Withdrawal by Subject | 0 | 1 | 0 |
| Cycle 2 and Beyond | Adverse Event | 1 | 0 | 0 |
| Screening | Failed to meet screening requirements. | 7 | 3 | 0 |
Baseline characteristics
| Characteristic | Phase I, Nivolumab Dose Lvl 1 (80mg IV Every 2 Weeks) | Phase I, Nivolumab Dose Lvl 2 (240mg IV Every 2 Weeks) | Phase 1b at Nivolumab MTD (240mg IV, Every 2 Weeks) | Total |
|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 4 Participants | 3 Participants | 0 Participants | 7 Participants |
| Age, Categorical Between 18 and 65 years | 4 Participants | 6 Participants | 0 Participants | 10 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants | 1 Participants | 0 Participants | 2 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 7 Participants | 8 Participants | 0 Participants | 15 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 2 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) White | 8 Participants | 6 Participants | 0 Participants | 14 Participants |
| Region of Enrollment United States | 8 participants | 9 participants | — | 17 participants |
| Sex: Female, Male Female | 2 Participants | 5 Participants | 0 Participants | 7 Participants |
| Sex: Female, Male Male | 6 Participants | 4 Participants | 0 Participants | 10 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 7 / 8 | 9 / 9 | 0 / 0 |
| other Total, other adverse events | 8 / 8 | 9 / 9 | 0 / 0 |
| serious Total, serious adverse events | 5 / 15 | 9 / 12 | 0 / 0 |
Outcome results
Primary
Maximum Tolerated Dose (MTD)
To identify maximum tolerated dose (MTD) of nivolumab for combination treatment of nivolumab following Y-90 in patients with advanced hepatocellular carcinoma. The MTD will be defined as the highest dose of nivolumab that causes dose limiting toxicities (DLTs) in \<2 of 6 patients. The Phase I portion of the study follows a 3+3 dose escalation design. Nivolumab has two dose levels: Level 1: 80mg IV every 2 weeks, Level 2: 240mg IV every 2 weeks. Toxicity will be assessed using the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE), version 4.03. A DLT is defined as an Adverse Event (AE) or abnormal laboratory value assessed as at least possibly related to the study medication, occurs ≤ 28 days (1 cycle) following the first dose of nivolumab and meets any of the criteria listed in the Protocol (Section 4.3.1).
Time frame: The first cycle of treatment with nivolumab (28 days)
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Phase I (Yttrium Y 90 Glass Microspheres, Nivolumab) | Maximum Tolerated Dose (MTD) | 240 mg of nivolumab, IV |
Primary
Phase IB: Objective Response Rate (ORR)
Evaluate tumor response by assessing the proportion of patients with Objective response rate (ORR) (according to RECIST v. 1.1 criteria) to the combination treatment of nivolumab with Y-90 by examining imaging scans. Per RECIST v. 1.1: Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10mm. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: At baseline and every 8 weeks for the first 13 months and then every 12 weeks up to 2 years
Population: Due to funding issues, Phase 1b of the study never opened to accrual.
Secondary
Disease Control Rate (DCR)
DCR will be determined at 24 weeks from the start of nivolumab treatment by the sum of complete response (CR), partial response (PR) and stable disease (SD) according to measurement of target and non-target lesions as assessed by RECIST v1.1 where generally the following definitions are true: CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10mm. PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum diameters while on study.
Time frame: At 24 weeks (6 months)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Phase I (Yttrium Y 90 Glass Microspheres, Nivolumab) | Disease Control Rate (DCR) | 4 Participants |
| Phase I, Nivolumab Dose Lvl 2 (240mg IV Every 2 Weeks) | Disease Control Rate (DCR) | 4 Participants |
Secondary
Number of Patients Who Experience Adverse Events
Safety and tolerability of toxicities (according to the NCCN CTCAE v4.03) and tolerability of nivolumab and y-90 in patients with advanced hepatocellular carcinoma as graded using CTCAE 4.03 that are grade 3 - 5 for patients determined to be evaluable for other endpoints. In general the following severity definitions are true: Mild (grade 1): the event causes discomfort without disruption of normal daily activities. Moderate (grade 2): the event causes discomfort that affects normal daily activities. Severe (grade 3): the event makes the patient unable to perform normal daily activities or significantly affects his/her clinical status. Life-threatening (grade 4): the patient was at risk of death at the time of the event. Fatal (grade 5): the event caused death.
Time frame: During treatment where (1 Cycle = 28 days) the range of cycles attempted was 1-14 and up to 100 days following the last administration of study drug
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Phase I (Yttrium Y 90 Glass Microspheres, Nivolumab) | Number of Patients Who Experience Adverse Events | Lymphocyte count decreased | 2 Participants |
| Phase I (Yttrium Y 90 Glass Microspheres, Nivolumab) | Number of Patients Who Experience Adverse Events | Abdominal pain | 1 Participants |
| Phase I (Yttrium Y 90 Glass Microspheres, Nivolumab) | Number of Patients Who Experience Adverse Events | Blood bilirubin increased | 1 Participants |
| Phase I (Yttrium Y 90 Glass Microspheres, Nivolumab) | Number of Patients Who Experience Adverse Events | Alkaline phosphatase increased | 1 Participants |
| Phase I (Yttrium Y 90 Glass Microspheres, Nivolumab) | Number of Patients Who Experience Adverse Events | Keratitis | 1 Participants |
| Phase I (Yttrium Y 90 Glass Microspheres, Nivolumab) | Number of Patients Who Experience Adverse Events | Thromboembolic event | 1 Participants |
| Phase I (Yttrium Y 90 Glass Microspheres, Nivolumab) | Number of Patients Who Experience Adverse Events | Aspartate aminotransferase increased | 0 Participants |
| Phase I (Yttrium Y 90 Glass Microspheres, Nivolumab) | Number of Patients Who Experience Adverse Events | Hyperglycemia | 0 Participants |
| Phase I (Yttrium Y 90 Glass Microspheres, Nivolumab) | Number of Patients Who Experience Adverse Events | Creatinine increased | 0 Participants |
| Phase I (Yttrium Y 90 Glass Microspheres, Nivolumab) | Number of Patients Who Experience Adverse Events | Investigations (other) | 1 Participants |
| Phase I, Nivolumab Dose Lvl 2 (240mg IV Every 2 Weeks) | Number of Patients Who Experience Adverse Events | Hyperglycemia | 2 Participants |
| Phase I, Nivolumab Dose Lvl 2 (240mg IV Every 2 Weeks) | Number of Patients Who Experience Adverse Events | Lymphocyte count decreased | 1 Participants |
| Phase I, Nivolumab Dose Lvl 2 (240mg IV Every 2 Weeks) | Number of Patients Who Experience Adverse Events | Thromboembolic event | 0 Participants |
| Phase I, Nivolumab Dose Lvl 2 (240mg IV Every 2 Weeks) | Number of Patients Who Experience Adverse Events | Abdominal pain | 0 Participants |
| Phase I, Nivolumab Dose Lvl 2 (240mg IV Every 2 Weeks) | Number of Patients Who Experience Adverse Events | Investigations (other) | 0 Participants |
| Phase I, Nivolumab Dose Lvl 2 (240mg IV Every 2 Weeks) | Number of Patients Who Experience Adverse Events | Blood bilirubin increased | 0 Participants |
| Phase I, Nivolumab Dose Lvl 2 (240mg IV Every 2 Weeks) | Number of Patients Who Experience Adverse Events | Aspartate aminotransferase increased | 1 Participants |
| Phase I, Nivolumab Dose Lvl 2 (240mg IV Every 2 Weeks) | Number of Patients Who Experience Adverse Events | Alkaline phosphatase increased | 0 Participants |
| Phase I, Nivolumab Dose Lvl 2 (240mg IV Every 2 Weeks) | Number of Patients Who Experience Adverse Events | Creatinine increased | 1 Participants |
| Phase I, Nivolumab Dose Lvl 2 (240mg IV Every 2 Weeks) | Number of Patients Who Experience Adverse Events | Keratitis | 0 Participants |
Secondary
Progression Free Survival (PFS) at 24 Weeks (6 Months)
Evaluate the percentage of patients alive and progression free at 24 weeks. PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. Progression assessment will be performed by investigator each time the patients has a radiologic evaluation after 8 weeks of treatment. In general Progressive Disease (PD) will be assessed using RECIST v1.1 and defined as: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm (0.5 cm). (Note: the appearance of one or more new lesions is also considered progression).
Time frame: Up to 24 weeks (6 months)
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Phase I (Yttrium Y 90 Glass Microspheres, Nivolumab) | Progression Free Survival (PFS) at 24 Weeks (6 Months) | 40 percentage of patients |
| Phase I, Nivolumab Dose Lvl 2 (240mg IV Every 2 Weeks) | Progression Free Survival (PFS) at 24 Weeks (6 Months) | 40 percentage of patients |
Other Pre-specified
Circulating Free DNA (cfDNA) Mutation Analyses
Change in clonal burden landscape will be analyzed to investigate its correlation with treatment response or development of resistance to treatment.
Time frame: Every 8 weeks for the first 24 weeks then every 16 weeks up to 2 years
Other Pre-specified
Expression Level of Biomarker of Inflammatory/Immune Signature
Evaluate biomarker expression level using immunohistochemistry or flow cytometry.
Time frame: Up to 2 years
Post Hoc
Overall Survival (OS)
OS is defined as the duration of time from start of treatment to time of death and is summarized using Kaplan-Meier product limit curve and estimates.
Time frame: Followed during treatment (1 Cycle = 28 days the range of cycles attempted was 1-14) and for up to 2 years during follow up
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Phase I (Yttrium Y 90 Glass Microspheres, Nivolumab) | Overall Survival (OS) | 14.65 months |
| Phase I, Nivolumab Dose Lvl 2 (240mg IV Every 2 Weeks) | Overall Survival (OS) | 4.50 months |
Other Pre-specified
PD-L1 Protein Expression
Tumor tissue will be used to examine expression of PD-L1 protein on tumor cells.
Time frame: At baseline